Tools   Select Another Resource Report Type

https://www.signalingpathways.org/ominer/query.jsf

THIS RESOURCE IS NO LONGER IN SERVICE.Documented on February 25, 2022.Software tool as knowledge environment resource that accrues, develops, and communicates information that advances understanding of structure, function, and role in disease of nuclear receptors (NRs) and coregulators. It specifically seeks to elucidate roles played by NRs and coregulators in metabolism and development of metabolic disorders. Includes large validated data sets, access to reagents, new findings, library of annotated prior publications in field, and journal covering reviews and techniques.As of March 20, 2020, NURSA is succeeded by the Signaling Pathways Project (SPP).

Proper citation: Nuclear Receptor Signaling Atlas (RRID:SCR_003287) Copy   

•   Source: SciCrunch Registry

http://www.store-a-tooth.com/

Provia Laboratories Inc. offers Store-A-Tooth, the industry-leading dental stem cell banking service for preserving the stem cells found in baby teeth and wisdom teeth. Store-A-Tooth is a service that provides you the opportunity to store the stem cells inside of teeth that come out. Eligible teeth include baby teeth, wisdom teeth, and other healthy teeth that need to be surgically extracted during the normal course of dental care. Store-A-Tooth has been available since 2006 from dentists across the U.S. At the core of our tooth transport device is the Save-A-Tooth device, which is FDA-approved and ADA accepted for the preservation of avulsed teeth. We use Save-A-Tooth for tooth collection and transport to ensure optimal viability of your sample for processing and cryopreservation. Our laboratory is FDA-registered, CLIA-certified, and AABB-accredited.

Proper citation: Store-a-Tooth Stem Cell Bank (RRID:SCR_004252) Copy   

•   Source: SciCrunch Registry

http://www.edarstudy.eu/

A European collaborative study to develop and validate new biomarkers for Alzheimer's disease. Central in the project is the development of an assay for the measurement of beta amyloid oligomers in cerebrospinal fluid and plasma. In order to validate the assay for beta amyloid oligomers, cerebrospinal fluid and plasma will be repeatedly collected in subjects with Alzheimer's disease, other types of dementia, mild cognitive impairment, and control subjects.

Proper citation: EDAR study: biomarkers for Alzheimer's disease (RRID:SCR_004445) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29358&a=31598&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. Project creating a DNA biobank from persons admitted to the neurointensive care unit of the Karolinska University Hospital to study possible genetic influences in traumatic brain injuries (TBI). Serum and cerebrospinal fluid sampled during the subacute phase are also collected. Samples were collected prospectively from clinically well characterized patients to allow for studies of association between candidate genes and clinical outcome parameters or biomarkers for relevant disease processes. The aim is to collect samples from 200-400 individuals. Samples will be collected from TBI patients at up to three different occasions. At first sampling, whole blood, serum and liquor will be collected and at the second and third occasions only serum and liquor.

Proper citation: KI Biobank - TBI (RRID:SCR_005897) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/imm/eims-an-epidemiological-investigation-of-risk-factors-for-multiple-sclerosis

A multi-center population based epidemiological investigation of risk factors for Multiple Sclerosis (MS), where lifestyle- and environmental factors are examined systematically with concurrent genetic information. Newly diagnosed cases of MS in a geographically defined population and randomly chosen controls are identified and asked to answer a questionnaire on lifestyle, previous exposures at work, home and during spare time activities. For both cases and controls blood samples are taken for analysis of putative risk genes since environmental exposures probably contributes to disease only in individuals with certain genotypes. Exposures of interest are different sociodemographic factors, smoking, sunlight exposure, oral contraceptives / hormonal factors, butyrophilin (a milk protein), vaccinations, infections, atopic disease, organic solvents, mineral oils and a number of different psychosocial factors, such as critical lifetime events. Data from more than 1600 cases and 3200 controls are currently collected. (August 2014) The intention is to continue with the data collection over several years in order to analyse how genes and environment interact. The study is a collaboration between different institutions at Karolinska Institutet and neurological centers from 38 different hospitals in Sweden. Sample types * EDTA whole blood * DNA * Plasma * Serum

Proper citation: KI Biobank - EIMS (RRID:SCR_005898) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/imm/gems-genes-and-environment-in-multiple-sclerosis

The study subjects invited to participate is chosen from the Swedish national Multiple Sclerosis registry and will number around 10 000 individuals to be included during two to three years. The same number of matched controls will also be included in the study. A pilot study with around 100 participants was performed during 2009, and the large scale study started in November 2009. Multiple sclerosis (MS) is a neurological disease that affects the central nervous system. It affects young people and the debut age is between 20 and 40 years. The disease comes with exacerbations but further on leads to disability. The incidence in Sweden is around 5 per 100 000 per year and the prevalence is 125 per 100 000 inhabitants. In total there are estimated around 13000 cases in Sweden and today 9000 of them are registered in the Swedish National Multiple Sclerosis register. Sample types * EDTA whole blood * DNA * Plasma Number of sample donors: 5592 (June 2010)

Proper citation: KI Biobank - GEMS (RRID:SCR_005893) Copy   

•   Source: SciCrunch Registry

http://www.geisinger.org/research/centers_departments/genomics/mycode/mycode.html

By collecting and analyzing blood samples from Geisinger''s large patient population, MyCode will help unlock the mysteries of some of the most devastating and debilitating diseases. Blood samples are obtained from patients of certain Geisinger specialty clinics to study specific conditions, such as obesity and cardiovascular disease, and also from patients of Geisinger primary care clinics to provide a representative sample of the regional population. More than 60,000 samples from over 23,000 Geisinger patients have been collected so far, and sample collection is ongoing. MyCode researchers use the blood samples to study the genetic causes of diseases and certain disease-related molecular mediators. Knowledge gained from these studies will allow researchers to pursue innovative approaches to disease prevention, diagnosis and treatment. To be of value for Genomic Medicine research, bio-banked samples must be connected to clinical data: MyCode allows genetic and molecular data about the samples to be connected to medical data in a way that protects patient identity. When a patient agrees to participate in MyCode, blood samples for the MyCode Project are collected during blood draws ordered as part of the patient''s routine medical care. After the sample is drawn and labeled, a staff member from the Weis Center for Research transports the blood to the Geisinger Clinic Genomics Core (GCGC) where it is processed for storage. At this stage, all personal identification markers are removed and the samples are assigned a randomly-selected identification number. A secure key is maintained that allows approved researchers to connect the samples to the clinical data for genomic studies in a way that ensures confidentiality of the information. To maintain confidentiality of MyCode data the code linking the research numbers and the electronic health records are kept in a password-protected files accessible only to MyCode team members. Additionally, all results generated from the samples are reported as a group so that individuals are not identified. The samples are stored indefinitely.

Proper citation: Geisinger Biobank (RRID:SCR_005652) Copy   

•   Source: SciCrunch Registry

http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=556465

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Develop, manufacture and market proprietary, nanocrystalline calcium-phosphate-based biomaterials that promote the repair and regeneration of bone damaged by trauma or disease. ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems.

Proper citation: ETEX Corporation (RRID:SCR_004685) Copy   

•   Source: SciCrunch Registry

http://www.nationalbiobanks.fi/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023.To guarantee the top level of expertise in modern genetic and biological analyses, we have built an infrastructure that facilitates the collection of genome-wide information on the genetic background of diseases as well as functional information on the molecules that are critical in the disease process. Furthermore we have established the necessary storage, database and computational resources for the expert analyses of the massive amount of collected biological information. Our scientific expertise, technology platforms and large nationwide sample collections facilitate a highly competitive environment for research and education in molecular medicine of the 21st century. The biobanking wet lab effort is concentrated to KTL/Biomedicum Large scale DNA extraction and storage facility. The facility presently houses DNA from more than 200 000 individuals and is co-ordinated by National Public Health Institute. It is equipped with state of the art bar coding system for sample tracking, an automated Gentra DNA extraction equipment, liquid handling robots, storage facilities, and tailor made data management tools for optimal confidentiality and quality control.

Proper citation: National Biobank of Finland (RRID:SCR_004679) Copy   

•   Source: SciCrunch Registry

http://www.ibcresearch.org/biobank/

The IBC Research Foundation BioBank is a secure, privacy-protected collection of biological specimens from ibc-diagnosed patients (cases, and, unlike the former George Washington University IBC Registry, ibc patients who have died, those who are under legal age, and those living but unable to make decisions for themselves, may be consented to participate in the IBC Research Foundation BioBank by their authorized representative) and from those not diagnosed with ibc (controls), volunteering following a consent decision making process, and signing an Informed Consent. Clinical Data and a comprehensive questionnaire will also be obtained for those diagnosed with ibc. The Inflammatory Breast Cancer Research Foundation (ibcRF) has established a BioBank and Clinical Database. The BioBank contains non-tumor RNA and DNA, tumor RNA and DNA, blocks and slides from diagnostic pathology, and medical records describing clinical and pathologic findings at diagnosis.

Proper citation: Inflammatory Breast Cancer Biobank (RRID:SCR_004556) Copy   

•   Source: SciCrunch Registry

http://www.pathology.med.ohio-state.edu/HTRN/apc/default.asp

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. The Adenoma Polyp Tissue Bank (APTB) receives whole blood from patients enrolled in the Prevention of Sporadic Colorectal Adenomas with Celecoxib clinical trial. We have reached our accrual on blood submissions, so we will no longer be receiving blood specimens The objectives of this trial are as follows: A. To determine the efficacy and safety of celecoxib versus placebo in preventing the occurrence of newly detected colorectal adenomas in subjects at increased risk for colorectal carcinoma. In addition to incidence, other established risk factors will be evaluated for their association with occurrence of new colorectal adenomas, including cancer family history and adenoma size, histopathologic grade, multiplicity and location. Primary assessment of treatment efficacy will be the reduction in the number of subjects with adenomas at colonoscopy after Year 1 and Year 3 of study drug use. Secondary assessments of treatment efficacy will be 1) the number of adenomas 2) the histopathologic grade of adenomas and 3) the size of adenomas, also measured after one year and three years of study drug use. These factors will be incorporated into a risk model for predicting adenoma occurrence and response to celecoxib. B. To determine the efficacy of celecoxib versus placebo in modulating one or more of a panel of biomarkers for colorectal cancer at the cellular and molecular level sampled in a subset of subjects at selective sites at baseline and after Year 1 and Year 3 of study drug use. These biomarkers will include measurements of aberrant crypt foci (ACF), proliferation (index and crypt distribution), apoptosis (index and crypt distribution), COX expression and activity. If modulation of one or more mucosal biomarkers occur, we will explore whether it correlates with the development of incident colorectal neoplasia (adenomas/carcinomas), thereby attempting to validate the surrogacy of that biomarker. C. To develop a specimen bank. Serum and white blood cells are isolated from whole blood and adenoma tissue blocks and slides are banked. Banked specimens will become available for use in correlative science studies at a later point. This project began in 1999 and will be extended through 2006. The lead principal investigator is Monica M. Bertagnolli, MD, Brigham and Women''s Hospital, Boston, MA, and the APTB Director is Scott Jewell, Ph.D., Department of Pathology, The Ohio State University. The APTB is supported by the NIH, NCI Division of Cancer Prevention, in connection with the Strang Cancer Prevention Center, Cornell University, New York., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Adenoma Polyp Tissue Bank (RRID:SCR_005366) Copy   

•   Source: SciCrunch Registry

http://www.bonebank.com

Bone Bank Allografts is the distributor of the SteriGraft line of high quality bone and soft tissue allografts to medical professionals. The company has been in existence for over 13 years and has helped doctors and their patients with over one hundred thousand successful transplantations. Bone and soft tissue allografts in the SteriGraft line are validated to a sterility assurance level (SAL) of 10(-6) in accordance with ISO 11137-2 Method 1. Bone Bank Allografts was founded in 1993 in response to a growing need for allograft tissue in South Texas. Since 1993, Bone Bank Allografts'' distribution network has grown to cover Texas, the country and the globe, fulfilling surgical needs for allograft tissue in more than 175,000 successful transplantations. Located in San Antonio, Texas, Bone Bank Allografts is dedicated to a just, equitable and fair distribution of cadaveric tissue to surgeons, hospitals, surgicenters and dental offices. Over the years, our customers have come to rely on the superior quality of our tissue products as well as the unmatched service of our well trained, certified Tissue Bank Specialists (CTBS) and our knowledgeable distribution staff. With accreditation from the American Association of Tissue Banks (AATB), registration with the U.S. Food and Drug Administration (FDA) and compliance with the FDA''s Good Tissue Practices, Bone Bank Allografts continues to pursue our mission: To enhance the quality of patient care by providing safe, high quality allograft tissues to health care professionals for transplant and research. Most recently, Bone Bank Allografts has taken the next important step in tissue banking by developing a powerful partnership with Texas Human Biologics (THB) in order to process donated human tissue.

Proper citation: Bone Bank Allografts (RRID:SCR_004432) Copy   

•   Source: SciCrunch Registry

http://www.ahcdc.ca/index.php/national-studies/blood-borne-pathogens

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. To develop a method to look for known and emerging blood borne diseases, a secure bank of samples has been established to test for known blood borne infectious agents and genetic changes causing or modifying the clotting disease, and to be available for testing for newly discovered viruses and clotting gene changes as they are found. The objectives of this project are: * To collect blood samples for a sample bank of plasma, DNA, and RNA to screen for known and emerging blood borne diseases. * To identify the mutation leading to each consenting patient''s bleeding disorder, and to characterize other known and yet to be discovered genes that affect blood coagulation. * To collect encoded, non-nominal data into a central database from an electronic chart known as CHARMS, which is currently kept in each hemophilia clinic in Canada to correlate with results from 1 and 2.

Proper citation: Blood Borne Pathogens Laboratory (RRID:SCR_004707) Copy   

•   Source: SciCrunch Registry

http://dtp.nci.nih.gov/branches/btb/services.html

National Cancer Institute Biorepositories provides information on the tumor repository, animal production program, and access to other NIH Repositories. A catalog of in vitro cell lines, transplantable animal and human tumors and microarrays, including ordering information, is available. In the Animal Production Program, rodents are supplied to Federal Institutions and to grantees/contractors with a current OLAW Assurance on file. Requests from international entities seeking rodent strains solely available from the NCI Animal Production Program must have an OLAW Assurance or current AAALACi accreditation and will be evaluated on a case-by-case basis. In general, the rodents are supplied to the following: * Researchers at NCI-Frederick * NIH on-campus laboratories * NIH/NCI funded research contracts * NIH/NCI funded grantees * Other government agencies To meet the above needs, animal production contracts plus quality control contracts are used. The animal production contracts are used to propagate the NIH sublines of the strains. Many of the strains produced are not available commercially and the NCI program is the sole source of several lines.

Proper citation: National Cancer Institute Biorepositories (RRID:SCR_004789) Copy   

•   Source: SciCrunch Registry

http://www.geenivaramu.ee/en/

The Estonian Biobank is the population-based biobank of the EGCUT. The project is conducted in accordance with the Estonian Genes Research Act and all participants have signed a broad informed consent form (www.biobank.ee and Metspalu 2004, Drug Dev. Res.). As of December 2011, the biobank contains 51,515 participants (gene donors). The database of genotypic, phenotypic, health and genealogical information represents about 5% of Estonia''s adult population, and is the largest cohort ever gathered in Estonia. The age, sex and geographical distribution of this cohort reflect the structure of the adult population in Estonia. The database enables to conduct research in order to find links between genes, environmental factors, lifestyles and complex diseases or other traits. Active use of the biobank has started and although the first users are researchers all over the world with hundreds of different projects currently underway, industry is also interested. At the international level, the EGCUT will join the BBMRI follow-up program (ERIC) and through this channel provide service (biobanking, genotyping, sequencing and data analysis) for the centers in Europe who need it. Currently, the first follow-up study is underway and the molecular information of the cohort will be increased. For example, we have over 12 000 DNA samples analyzed by high density genotyping arrays and over 10 000 plasma samples analyzed by NMR scans, over 1000 individuals with RNA expression arrays, 2000 individuals with clinical laboratory analysis (over 40 tests) and over 60 full genomes are under deep sequencing. The infrastructure of the EGCUT includes a laboratory for DNA genotyping and next generation sequencing all based on Illumina platforms (HiScanSQ, HiSeq2000 and robotics), an IT unit (databases) with required computing power and storage space (1.2PB), data analysis team (bioinformatics and statistical genetics) and last but not least, a patient recruitment unit (health records, lifestyle and environmental information and biological samples ����?����������?? DNA, plasma and WBC from all 51515 gene donors). This is all located on 1000m2 in a brand new laboratory building, Riia str 23, Tartu, Estonia.

Proper citation: Estonian Genome Center (RRID:SCR_004467) Copy   

•   Source: SciCrunch Registry

http://www.oncoreuk.org/

No longer functioning as an independent charity, onCore UK is a national cancer biobanking organization. Our mission is to serve as an action team that informs, coordinates and develops cancer biobanking to enable research towards the discovery and development of new interventions against cancer. We also offer advice to researchers who need to collect and store samples for their own specific projects. Our main strategic objectives are: * To empower research using human biosamples to find new and effective means of preventing, detecting or treating cancer. * To improve access by researchers to the human biosamples they require for their work. * To facilitate an environment in which patients, the public, health professionals, researchers, funders of research, policy makers and regulators can work together to support cancer biobanking and the research it underpins. * To provide practical information, coordination and development for current and future people and organizations involved in cancer biobanking to ensure that they are not unnecessarily hindered in their work. * To provide an accurate and regularly updated picture of the cancer biobanking provision in the UK that will inform future decisions by funders supporting research using donated human biosamples. * To distribute the human biosamples that onCore UK has in its custody. onCore UK conducts its business within the overall scope of the National Cancer Research Institute (NCRI) and for the benefit of cancer research. In the past we have also worked with selected NHS hospitals in different parts of the country to collect biosamples and relevant clinical data donated by cancer patients. These biosamples are stored in a secure repository and researchers can apply to use them. We make anonymized biosamples and data available for scientifically and ethically approved research on a cost-recovery basis. onCore UK works with other cancer biobanks in the UK via the NCRI Confederation of Cancer Biobanks (CCB), and with other biobanks internationally, to improve access for researchers to larger numbers of high quality biosamples, to harmonize how biobanks work and to share expertise for the benefit of all involved.

Proper citation: onCore UK (RRID:SCR_004348) Copy   

•   Source: SciCrunch Registry

http://www.partners.org/researchcores/clinical/specimen_BWH.html

The Crimson Biospecimen Core prospectively collects discarded clinical materials matching investigator-defined criteria. Queries are run against real-time data on recently received clinical samples, including ICD.9 codes and results of clinical laboratory testing. Studies using the core must either (1) have an IRB-approved protocol for discarded clinical materials and anonymized information or (2) a protocol to allow collection of discarded samples from patients consented for their study. Collected samples may be additionally processed, aliquotted, or tested per the menu of tests available within the BWH and MGH Clinical Laboratories and Partners Genomics Center. Services: * Collection of discarded clinical specimens including serum, plasma, CSF, urine and microbiological isolates for IRB-approved studies. * Processing or additional clinical testing of collected materials. * Ability to receive consented patient samples for processing and clinical testing. * Online interface to manage collected sample inventories, associated test results, and study users/workgroup per IRB-approval.

Proper citation: Crimson Biospecimen Core (RRID:SCR_004451) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/HuREF/?SsId=78

The Human Reference Genetic Material Repository makes available DNA from a single individual, J. Craig Venter, whose genome has been sequenced and assembled. The DNA samples are prepared from a lymphoblastoid cell line established at Coriell Cell Repositories from a sample of peripheral blood. The DNA samples are available in 50 microgram aliquots. The lymphoblastoid cell line is not available for distribution. The human DNA sample provided is that of J. Craig Venter whose DNA from white blood cells and sperm was sequenced using Sanger chemistry (ABI Capillary Electrophoresis Platforms 3700 and 3730xl), assembled using the Celera Assembler and was published in PLoS Biology . J. Craig Venter, born on 14 October 1946, is a Caucasian male of self-reported European-American ancestry. The data available on this sample, whose genome assembly is referred to as HuRef, includes: * Whole Genome Shotgun Sequencing data * Sequence trace set deposited by JCVI in the NCBI trace archive * Human Genome Browser displaying sequence assembly, DNA variants and gene annotations Additional data sets from this study include: * Full set of Sanger reads used for genome assembly * SNP and insertion/deletion variant on the human genome sequence coordinates (NCBI version 36) * Affymetrix 500K GeneChip data * Illumina HumanHap650Y Genotyping BeadChip data Given the amount of data publicly available the genomic content of this sample, HuRef will be useful as a reference for many genetic studies.

Proper citation: Human Reference Genetic Material Repository (RRID:SCR_004693) Copy   

•   Source: SciCrunch Registry

http://www.biomax.us/

Our robust searchable Tissue Bank database at US Biomax contains normal, non-cancerous disease and cancer samples, just a fraction of total paraffin tissue bank. Use advanced search function to define your search. Some of them have H&E images. Our tissue repository, tissue bank has huge paraffin tissue blocks, a large selection of histology tissue section slides of human cancer, normal tissue, rhesus and cynomolgus normal fresh frozen tissue as well as paraffin blocks and slides. It has also normal human organs in paraffin embedded tissue blocks as well as rhesus and cynomolgus monkey normal organ tissues. Snap frozen (fresh frozen) tissue of rhesus/cynomolgus monkey are also available. We also provide tissue array, custom tissue microarray (with samples you provided or from our tissue bank) as well as OEM services. Other products/services available include tissue microarray, paraffin tissue sections, histology services and quantitative telomerase detection kit.

Proper citation: US Biomax (RRID:SCR_004295) Copy   

•   Source: SciCrunch Registry

http://www.uthouston.edu/uth-big/Projects/BioBank.htm

The University of Texas Health Science Center at Houston (UTHealth) Clinical and Translational Sciences (CCTS) BioBank employs a federated rather than a centralized model which encourages participation by sample owners who are concerned about guaranteeing their ownership of samples and sample information about patients, samples and related clinical data. In a federated model, individual sites agree on shared policies and procedures for data and sample sharing and oversight. Samples remain with and are governed by the contributing principal investigator at each site. The contributing investigator has final authority whether or not to collaborate or to release samples to qualified researchers. The goal of SLED (Sample Location and Enhanced Distribution) is to help researchers overcome two of the biggest obstacles preventing their research from beginning: 1) location of samples and related data, and 2) requesting of samples and related data. Prior to SLED''s inception the existing system was limited to providing links to samples and data and relying on phone calls to sample owners to facilitate sharing. Collaboration between the CTSA Biobank Consortium and the informatics team at the University of Texas School of Biomedical Informatics is ongoing during this effort. The initial design was constructed using best practices offered by NIH, NCI, and other biobank industry leaders to support and to improve synergy and interaction among various research efforts. Through SLED, researchers will be able to search for samples using a variety of criteria including availability, clinical data, consent criteria, patient demographics, patient diagnoses, study data, and sample type at local and national biobank sites.

Proper citation: UTHealth BioBank (RRID:SCR_004570) Copy   

•   Source: SciCrunch Registry